SCHEMBL25819373

SCHEMBL25819373

C[C@@H](C(=O)N1C(=O)OC[C@H]1Cc1ccccc1)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.51
STS P08842 1/20 0.44
KLK7 P49862 2/20 0.44
KLK5 Q9Y337 1/20 0.44
PPARA Q07869 1/20 0.43
GAA P10253 1/20 0.42
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
MMP13 P45452 1/20 0.40
P2RX7 Q99572 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7497146 1.00 GPR119 (0.51) GPR119STSKLK7KLK5PPARA
SCHEMBL7496058 1.00 GPR119 (0.51) GPR119STSKLK7KLK5PPARA
SCHEMBL29922276 0.95 GPR119 (0.49) GPR119STSKLK7KLK5PPARA
SCHEMBL7989927 0.87 GPR119 (0.45) GPR119STSKLK7KLK5PPARA
SCHEMBL7989930 0.87 GPR119 (0.45) GPR119STSKLK7KLK5PPARA
SCHEMBL22764724 0.86 GPR119 (0.46) GPR119STSKLK7KLK5PPARA
SCHEMBL28709765 0.86 GPR119 (0.46) GPR119STSKLK7KLK5PPARA
SCHEMBL30136001 0.85 PPARA (0.47) PPARAGAASMN1; SMN2LMNAALDH1A1
SCHEMBL4610684 0.85 GPR119 (0.44) GPR119STSKLK7KLK5PPARA
SCHEMBL4611162 0.85 GPR119 (0.44) GPR119STSKLK7KLK5PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116322700-B Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-08-20 CN disclosed
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
CN-116322700-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2023-06-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 GPR119 4495/4885STS 4535/4885KLK7 3100/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 GPR119 4626/4885STS 4426/4885KLK7 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.